UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A (No.2)
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 5, 2012
GENESIS BIOPHARMA, INC
(EXACT NAME OF COMPANY AS SPECIFIED IN ITS CHARTER)
|
NEVADA
|
000-53172
|
75-3254381
|
||
|
(STATE OR OTHER JURISDICTION)
OF INCORPORATION) |
(COMMISSION FILE NUMBER)
|
(I.R.S. EMPLOYER
IDENTIFICATION) |
11500 Olympic Boulevard, Suite 400, Los Angeles CA 90064
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (866) 963-2220
N/A
(Former name or former address, if changed since last report)
|
|_|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR230.425)
|
|
|_|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
|
|
|_|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under theExchange Act (17 CFR 240.14d-2(b))
|
|
|_|
|
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
Effective January 5, 2012, Genesis Biopharma, Inc. (the “Company”) entered into a third amendment with all the holders of the Company’s previously issued Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes (the “Notes”) whereby the maturity date of the Notes has been further extended from January 5, 2012 to January 13, 2012.
The foregoing description of the Amendment No.3 to the Notes does not purport to be complete and is qualified in its entirety by the form of Amendment No. 3 to the Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes attached hereto as Exhibits 10.1 and which is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS
|
Exhibit No.
10.1 |
Description
Form of Amendment No. 3 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GENESIS BIOPHARMA, INC.
|
|||
|
Date: January 9, 2011
|
By:
|
/s/ Anthony J. Cataldo | |
|
Anthony J. Cataldo, Chairman, Chief Executive
Officer and President
|
|||
